Versions Compared
Key
- This line was added.
- This line was removed.
- Formatting was changed.
Summary
Principal Investigator: Jeffrey. Bradley, MD
Primary Objective:
To compare the overall survival of patients treated with high-dose versus standard-dose conformal radiation therapy in the setting of concurrent chemotherapy; To compare the overall survival of patients treated with cetuximab versus without cetuximab in the setting of concurrent chemotherapy.
Patient Population:
Newly diagnosed unresectable Stage III A or B non-small cell lung cancer (NSCLC); patients who present with N2 or N3 disease and an undetectable NSCLC primary tumor also are eligible; patients with supraclavicular or contralateral hilar adenopathy are ineligible.
- RTOG 0617: CT, Structures, RT Doses, RT Plans sent to ITC
For more information about the original aims of this trial please see this Protocol document: https://www.rtog.org/LinkClick.aspx?fileticket=EmCYRSsCnRA%3d&tabid=40
Localtab Group | ||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Image Added